Trials Sponsors Conditions Drugs Pricing

Conditions

Attention Deficit Disorder With Hyperactivity

Keywords

Attention-deficit hyperactivity disorderadultdiagnostic validityneuropsychological functionssocial functioning

Eligibility Criteria

Age18 Years - 45 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64)

Sampling MethodNon-Probability Sample

Study Population

community sample \& clinical sample

You may qualify if:

Case group:
Case group I: The cases with childhood ADHD diagnosis diagnosed as ADHD after interview Case group II: The cases with sufficient ADHD symptoms for diagnosis as DSM-IV ADHD at childhood but never assessed or treated for ADHD in childhood
Control group：The subjects without the DSM-IV-TR diagnosis of ADHD or any major psychiatric disorders.

You may not qualify if:

Comorbid with DSM-IV-TR diagnosis of pervasive developmental disorder, schizophrenia, schizoaffective disorder, delusional disorder, other psychotic disorder, organic psychosis, schizotypal personality disorder, bipolar affective disorder, severe anxiety disorder(such as OCD, ASD or PTSD) and mental retardation.

Sponsors & Collaborators

National Taiwan University Hospital
Otherlead

Study Sites (1)

National Taiwan University Hospital

Taipei, 10002, Taiwan

Related Publications (2)

Candido RCF, Menezes de Padua CA, Golder S, Junqueira DR. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2021 Jan 18;1(1):CD013011. doi: 10.1002/14651858.CD013011.pub2.
PMID: 33460048DERIVED
Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2013 Oct;16(9):1959-73. doi: 10.1017/S1461145713000357. Epub 2013 May 14.
PMID: 23672818DERIVED

MeSH Terms

Conditions

Attention Deficit Disorder with HyperactivitySocial Adjustment

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental DisordersSocial BehaviorBehavior

Study Officials

Susan Shur-Fen Gau, MD, PhD
Dept of Psychiatry, National Taiwan University Hospital
PRINCIPAL INVESTIGATOR

Enrollment

1,120 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: OTHER
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 29, 2007

First Posted

October 30, 2007

Study Start

October 1, 2007

Actual (reported)

Clinical and Neuropsychological Validity of Attention-Deficit Hyperactivity Disorder in Adulthood

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (2)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations